ReviewClinical microbiology reviews1990
Vaccinia virus vectors: new strategies for producing recombinant vaccines.
Review in Clinical microbiology reviews, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Efficacy and immunogenicity of rKVAC85B in a BCG prime-boost regimen against H37Rv and HN878 Mycobacterium tuberculosis strains.PloS one · 2025Article
- Assessing the generation of tissue resident memory T cells by vaccines.Nature reviews. Immunology · 2023Review
- Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge.NPJ vaccines · 2021Article
- Review
- Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.Cancers · 2018Article
- Article
- Review
- Somatostatin receptor based imaging and radionuclide therapy.BioMed research international · 2015Review
- Expression of herpes simplex virus type 1 DNA polymerase by recombinant vaccinia virus.Virus genes · 2009Article
- Vaccinia virus entry, exit, and interaction with differentiated human airway epithelia.Journal of virology · 2007Article
- Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism.Advanced drug delivery reviews · 2005Review
- Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.Journal of virology · 2002Article
- Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes.Journal of virology · 1996Article
- Pasteurella multocida produces a protein with homology to the P6 outer membrane protein of Haemophilus influenzae.Infection and immunity · 1995Article
- Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).Journal of virology · 1995Article
- Genetic recombination of pseudorabies virus: evidence that homologous recombination between insert sequences is less frequent than between autologous sequences.Archives of virology · 1995Article
- Expression of Aleutian mink disease parvovirus capsid proteins by a recombinant vaccinia virus: self-assembly of capsid proteins into particles.Journal of virology · 1992Article
- Modulation of experimental autoimmunity: treatment of adjuvant arthritis by immunization with a recombinant vaccinia virus.Infection and immunity · 1991Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The development and continued refinement of techniques for the efficient insertion and expression of heterologous DNA sequences from within the genomic context of infectious vaccinia virus recombinants are among the most promising current approaches towards effective immunoprophylaxis against a variety of protozoan, viral, and bacterial human pathogens. Because of its medical relevance, this area is the subject of intense research interest and has evolved rapidly during the past several years. This review (i) provides an updated overview of the technology that exists for assembling recombinant vaccinia virus strains, (ii) discusses the advantages and disadvantages of these approaches, (iii) outlines the areas of outgoing research directed towards overcoming the limitations of current techniques, and (iv) provides some insight (i.e., speculation) about probable future refinements in the use of vaccinia virus as a vector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.